Cationic Lipid Composition for Extrahepatic Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cationic lipid compounds for delivering biologically active substances face challenges in safety, efficacy, and specificity, with increased complexity leading to toxicity concerns that limit their clinical application.
Innovation Solution
Development of a novel cationic lipid compound with a unique structure, including two tertiary amine groups and specific alkylene and alkyl groups, which is used in a composition to enhance delivery of therapeutic and prophylactic agents, such as nucleic acids, with improved encapsulation efficiency, reduced cytotoxicity, and targeted organ delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipid compounds are used for delivering biologically active substances, then delivery capability is achieved, but toxicity increases and safety decreases
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as chain length, saturation degree, and head group composition to develop compounds with improved safety profiles. Specifically, the invention uses cationic lipids with tailored structures (e.g., DC-Chol, DOTAP variants) that maintain delivery efficacy while reducing cytotoxicity and off-target effects compared to conventional lipids like DOTMA.
Solution Approach 2:
The patent employs composite lipid formulations combining multiple lipid components (cationic lipids, neutral lipids, structured lipids, and polymer-conjugated lipids) to achieve synergistic effects. This composite approach allows the system to maintain effective gene delivery while reducing individual component toxicity, as demonstrated in LNP formulations for siRNA and mRNA delivery.
2Reliability
If lipid nanoparticle complexity is increased to improve delivery efficacy, then transfection efficiency improves, but production complexity increases and toxicity may increase
Solution Approach 1:
The patent segments the lipid nanoparticle into distinct functional components with specific roles: cationic lipids for complexation and transfection, neutral lipids for structural integrity, structured lipids for stability, and PEGylated lipids for steric stabilization. This segmentation allows each component to be optimized independently while simplifying the overall production process through standardized formulation approaches.
Solution Approach 2:
The patent develops universal LNP platforms that can deliver various therapeutic payloads (siRNA, mRNA, DNA) using the same core lipid formulation architecture. This multi-functionality reduces production complexity by establishing reusable, scalable manufacturing processes that don't require complete re-optimization for each new therapeutic agent.
3Reliability
If conventional cationic lipids are used, then general delivery is achieved, but targeted delivery to specific organs is limited
Solution Approach 1:
The patent modifies lipid properties to achieve local quality changes that enable organ-specific targeting. By adjusting lipid composition, charge density, and surface characteristics, the formulation can be optimized for specific target organs (e.g., liver, spleen, lung) while maintaining stability during circulation. This is achieved through controlled variations in lipid head groups and acyl chain structures.
Solution Approach 2:
The patent employs intermediary elements such as PEGylated lipids and surface-modified components that act as mediators between the lipid core and the biological environment. These intermediaries provide stealth properties for extended circulation and can be functionalized with targeting ligands to direct the nanoparticle to specific organs, thereby achieving targeted delivery without compromising overall formulation versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipid compound achieves significantly higher transfection efficiency, reduced cytotoxicity, and sustained mRNA expression in animals, with reduced liver toxicity and direct delivery to the spleen, enhancing the effectiveness and safety of nucleic acid delivery.
Implementation Method 1
Compositions, liposomes and liposome complexes (lipoplexes) containing a cationic lipid have been demonstrated as delivery carriers to effectively deliver biologically active substances
Implementation Method 2
Cationic and/or ionizable lipids include, for example, amine-containing lipids that can be readily protonated
Data Source
AI summary
Provided in the present disclosure is a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, which is an extrahepatic targeted cationic lipid compound with high efficiency and low toxicity. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic or prophylactic agent.